This site is intended for Healthcare Professionals only.

Reckitt recalls two infant formula powders over safety concerns

Date:

Share post:

The company has contacted all stores and pharmacies that are supplying these products

Reckitt has recalled certain catches of Nutramigen LGG stage 1 and stage 2 Hypoallergenic Formula powders over the possible presence of Cronobacter sakazakii.

While the products, which are used for special medical purposes for infants, are mainly prescribed, they are also available without a prescription.

The precautionary step has been taken after an isolated overseas sample of the product tested positive for Cronobacter sakazakii, said the consumer goods company, adding that a thorough investigation is on.

Cronobacter sakazakii is a type of bacteria that can easily survive in dry foods, like powdered infant formula, powdered milk, herbal teas, and starches.

The consumer goods company cautioned that the germ can cause fever and diarrhoea, and in severe cases may lead to sepsis or meningitis, which can cause symptoms like poor feeding, irritability, temperature changes, jaundice (yellow skin and whites of the eyes) and abnormal breaths and movements in infants.

The products being recalled are:

  • Nutramigen LGG Stage 1 Hypoallergenic Formula (400g), batch code ZL3F7D, Expiry date – 1st July 2025
  • Nutramigen LGG Stage 2 Hypoallergenic Formula (400g), batch code ZL3FAA, Expiry date – 1st July 2025
  • Nutramigen LGG Stage 2 Hypoallergenic Formula (400g), batch code ZL3FDM, Expiry date – 1st July 2025

They have contacted all stores and pharmacies that are supplying these products, as well as issued a recall notice to its customers.

“If you have purchased or been prescribed any of the above product batches, do not feed it to your baby and return to the place of purchase.

“If you have any concerns about the health of your baby, please seek medical advice,” the company said.

Reckitt has confirmed that no other batches of Nutramigen LGG Stage 1 and stage 2, and no other Nutramigen products in the range are affected, and these remain safe to use.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Surge in stroke cases could cost UK £75bn by 2035, charity warns

By 2035, there will be 151,000 hospital admissions due to stroke every year, averaging 414 admissions per day...

NHS and i.AI forge historic collaboration to boost healthcare

AI assisting NHS to half treatment times for stroke patients and overall patient care experience The Department of Health...

NHS to cut the red tape to support 50K NHS postgraduate doctors

New measures are part of NHS' broader efforts to retain its skilled workforce and ensure high-quality patient care  In...

England to roll out first targeted treatment for childhood brain tumours ‘gliomas’

The treatment has been found to slow the progression of gliomas by over threefold compared to standard chemotherapy  After...